Faculty Summaries
Igor Astsaturov, MD, PhD
Igor Astsaturov, MD, PhD
Assistant Professor
  • Attending Physician, Medical Oncology
  • Sterol Pathway Regulators of EGFR Signaling
    Andrey Gorin

    We have identified a critical step in the sterol biosynthesis pathway that when blockaded causes synthetic lethality with anti-EGFR drugs. Blockade of this unique step produces metabolites that may mediate enhanced apoptosis in multiple cancer cell lines. We are performing analysis of the mechanism by which the sterol biosynthetic enzymes and/or metabolites enhance apoptosis and downregulate EGFR signaling. We are also interested in developing pharmacological inhibitors of this irreversible step in the sterol pathway, or potentially other enzymes with similar biologic activities, as a means of translating this observation to the clinic.

  • Dual Specificity Phosphatases (DUSPs)
    Tetyana Bagnyukova

    A family of DUSP proteins regulates activity of the MAP kinases ERK, JNK and p38, which determine cellular fate when EGFR signaling is suppressed with specific inhibitors. Some of the DUSP family members are overexpressed in cancers. The function of individual DUSP in regulating the apoptosis of cancer cells is poorly understood. We are studying the protein-protein interactions of two DUSP proteins, with the goal of identifying the mechanism by which these specific DUSP family members can influence resistance to EGFR targeting by inhibitors. 

  • Synergy Between Aurora Kinase and EGFR Inhibitors
    In collaboration with Hossein Borghaei

    Capitalizing on our recent finding of synergy between inhibitors of EGFR and Aurora kinase A, clinical trials of an Aurora kinase inhibitor with cetuximab and erlotinib are being developed for the treatment of patients with head and neck cancers, and lung cancers.